A RUDN University chemist created anti-tumour compounds that are up to 80 times more effective than their counterparts
A RUDN University chemist created anti-tumour compounds that are up to 80 times more effective than their counterparts
A chemist from RUDN University has created platinum complex compounds that are superior in activity to cisplatin, the drug for the treatment of tumour diseases. The new compounds turned out to be also less toxic to healthy cells.

Platinum-based anticancer drugs — cisplatin, oxaliplatin, and carboplatin — are used for chemotherapy in about half of cancer cases. They penetrate cells and interact with DNA molecules. The process is fatal for rapidly dividing cancer cells because the drugs prevent the duplication of DNA molecules, which is necessary for successful division. Since cancer cells divide rapidly, they are the first to be affected. Still, platinum derivatives have certain disadvantages: low stability under physiological conditions and high toxicity.

To create new drugs, a strategy that involves the development of hybrid molecules is often used in modern chemistry. Such substances consist of two or more active fragments that are linked by a linker into one molecule. They usually have a double action, characteristic of each of the fragments.

A chemist from RUDN University, candidate of biological sciences Kirill Kirsanov, created a series of new drugs: hybrids of cisplatin, lonidamine, and bexarotene. Lonidamine itself has an anti-tumour effect due to its ability to suppress energy metabolism in cancer cells. In combination with radiation therapy, it is used to treat brain tumours. Bexarotene is used for the treatment of lung cancer and breast cancer, as it inhibits the growth of tumour cells of hematopoietic and squamous origin.

A derivative of cisplatin with bexarotene turned out to be the most promising. A combination of succinic acid and ethylenediamine was used as a linker. In tests conducted on four tumour cell lines, the hybrid drug was 80 times more active than bexaroten and 20 times higher on average than cisplatin, and the new drug was 80 times more active than cisplatin on MCF7D cell line. Based on the resulting leading compound, new and more effective anti-tumour medications can be developed.

The paper was published in the journal Inorganica Chimica Acta.

All news
23 Sep
RUDN chemist creates catalyst to produce anti-mosquito substances

A chemist from RUDN University has developed a catalyst for the production of eugenol acetate, a substance that destroys the larvae of mosquitoes transmitting dangerous diseases, being a safe chemical for human health.

18 Sep
RUDN soil scientists developed a new method for assessing soil fertility

RUDN soil scientists have revealed a direct correlation between the rate of soil formation of carbon dioxide, called CO2 emissions, and the content of microbial biomass in it. It is known that CO2 emission from soil is mainly conditioned by respiration of soil microorganisms and plant roots. The more CO2 soil emits, the more microbial biomass it usually contains. It was shown that CO2 emission by chernozem of different ecosystems (or different types of land use) correlates with the content of microbial biomass, and most closely with the rate of its microbial respiration. And the soil with good microbial properties has the “best quality”, is more fertile, provides the highest yield of crops and other plant biomass.

17 Sep
RUDN chemist developed a new catalyst for “green” biofuels

A RUDN chemist has synthesized a catalyst for the production of gamma-valerolactone — an energy-intensive “green” biofuel. The catalyst based on zirconium dioxide and zeolite has shown high efficiency in converting the waste of wood plant materials — methyl levulinate — to gamma-valerolactone.